Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
LI2-H5253-100ug
$310.00
LI2-H5253-1mg (500ug X 2)
$1855.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    LILRB2, ILT4, LIR2, MIR10, CD85d

  • Source

    Human LILRB2, Fc Tag (LI2-H5253) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Val 461 (Accession # AAH36827.1).

    Predicted N-terminus: Gln 22

    Request for sequence
  • Molecular Characterization

    LILRB2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 74.2 kDa. The protein migrates as 95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    LILRB2 SDS-PAGE

    Human LILRB2, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    LILRB2 SEC-MALS

    The purity of Human LILRB2, Fc Tag (Cat. No. LI2-H5253) is more than 95% and the molecular weight of this protein is around 160-190 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LILRB2 ELISA

    Immobilized Human LILRB2, Fc Tag (Cat. No. LI2-H5253) at 1 μg/mL (100 μL/well) can bind Anti-LILRB2 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

    Protocol
  •  LILRB2 ELISA

    Serial dilutions of Monoclonal Anti-LILRB2 Antibody, Human IgG1 were added into Human LILRB2, Fc Tag (Cat. No. LI2-H5253) : Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein, His,Avitag (Cat. No. HLG-H52E9) binding reactions. The half maximal inhibitory concentration (IC50) is 0.70 μg/mL (Routinely tested).

    Protocol
  •  LILRB2 ELISA

    Immobilized Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Cat. No. HLM-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human LILRB2, Fc Tag (Cat. No. LI2-H5253) with a linear range of 0.6-10 ng/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Recent Advances

 
Drug Development Progress
  • English Name:

    Leukocyte immunoglobulin-like receptor subfamily B member 2

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    11 Details

  • Highest Development Stage:

    Phase 2 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland